William Blair Estimates AbbVie’s FY2025 Earnings (NYSE:ABBV)

AbbVie Inc. (NYSE:ABBV) – Stock analysts at William Blair lowered their FY2025 EPS estimates for shares of AbbVie in a report issued on Tuesday, January 21st. William Blair analyst M. Phipps now forecasts that the company will earn $12.02 per share for the year, down from their previous estimate of $12.11. The consensus estimate for AbbVie’s current full-year earnings is $10.06 per share.

ABBV has been the topic of a number of other research reports. Barclays lifted their price target on shares of AbbVie from $200.00 to $212.00 and gave the company an “overweight” rating in a research report on Monday, October 7th. Citigroup cut their target price on shares of AbbVie from $226.00 to $215.00 and set a “buy” rating for the company in a research report on Tuesday, November 12th. BMO Capital Markets lowered their price target on AbbVie from $228.00 to $208.00 and set an “outperform” rating on the stock in a research report on Tuesday, November 12th. TD Cowen boosted their price objective on AbbVie from $195.00 to $225.00 and gave the stock a “buy” rating in a research report on Monday, October 7th. Finally, Daiwa Capital Markets lowered AbbVie from an “outperform” rating to a “neutral” rating and set a $180.00 target price on the stock. in a report on Thursday, December 5th. Five research analysts have rated the stock with a hold rating, seventeen have given a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $205.50.

AbbVie Stock Performance

Shares of NYSE ABBV opened at $169.19 on Wednesday. The business’s 50-day simple moving average is $175.75 and its 200-day simple moving average is $184.84. The company has a debt-to-equity ratio of 9.64, a quick ratio of 0.54 and a current ratio of 0.65. AbbVie has a 52 week low of $153.58 and a 52 week high of $207.32. The firm has a market cap of $298.98 billion, a price-to-earnings ratio of 58.75, a P/E/G ratio of 1.69 and a beta of 0.58.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Wednesday, October 30th. The company reported $3.00 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.92 by $0.08. The firm had revenue of $14.46 billion during the quarter, compared to analysts’ expectations of $14.28 billion. AbbVie had a return on equity of 244.01% and a net margin of 9.22%. The business’s revenue for the quarter was up 3.8% on a year-over-year basis. During the same quarter last year, the firm earned $2.95 earnings per share.

Hedge Funds Weigh In On AbbVie

Several institutional investors have recently modified their holdings of the stock. Resources Management Corp CT ADV lifted its stake in AbbVie by 0.5% in the second quarter. Resources Management Corp CT ADV now owns 81,355 shares of the company’s stock valued at $13,954,000 after buying an additional 383 shares in the last quarter. Providence Capital Advisors LLC lifted its position in AbbVie by 1.1% in the 2nd quarter. Providence Capital Advisors LLC now owns 16,101 shares of the company’s stock valued at $2,762,000 after acquiring an additional 169 shares in the last quarter. Mill Creek Capital Advisors LLC boosted its stake in AbbVie by 9.2% in the 2nd quarter. Mill Creek Capital Advisors LLC now owns 3,737 shares of the company’s stock worth $641,000 after purchasing an additional 316 shares during the period. Distillate Capital Partners LLC increased its holdings in AbbVie by 364,292.5% during the 2nd quarter. Distillate Capital Partners LLC now owns 291,514 shares of the company’s stock worth $50,000,000 after purchasing an additional 291,434 shares in the last quarter. Finally, Semmax Financial Advisors Inc. raised its stake in shares of AbbVie by 33.0% in the 2nd quarter. Semmax Financial Advisors Inc. now owns 589 shares of the company’s stock valued at $101,000 after purchasing an additional 146 shares during the period. 70.23% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at AbbVie

In other AbbVie news, SVP Kevin K. Buckbee sold 1,800 shares of the company’s stock in a transaction on Monday, December 16th. The shares were sold at an average price of $172.24, for a total transaction of $310,032.00. Following the completion of the sale, the senior vice president now owns 6,983 shares in the company, valued at approximately $1,202,751.92. The trade was a 20.49 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 0.25% of the stock is currently owned by company insiders.

AbbVie Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, February 14th. Stockholders of record on Wednesday, January 15th will be paid a dividend of $1.64 per share. This is a boost from AbbVie’s previous quarterly dividend of $1.55. This represents a $6.56 annualized dividend and a dividend yield of 3.88%. The ex-dividend date of this dividend is Wednesday, January 15th. AbbVie’s dividend payout ratio is 227.78%.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.